1414806-55-5

Basic information

• Product Name: (S,E)-2-(5-(4-(4-fluorobenzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid
• Synonyms: (S,E)-2-(5-(4-(4-fluorobenzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid
• CAS NO: 1414806-55-5
• Molecular Weight: 493.58
• Mol File: 1414806-55-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S,E)-2-(5-(4-(4-fluorobenzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S,E)-2-(5-(4-(4-fluorobenzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid(1414806-55-5)
• EPA Substance Registry System: (S,E)-2-(5-(4-(4-fluorobenzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid(1414806-55-5)

Safety Data

• Hazardous Substances Data: 1414806-55-5(Hazardous Substances Data)

Upstream product

• 63-91-2 L-phenylalanine 
• 161192-25-2 (S)-2-(4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid 
• 56442-17-2 4-((4-fluorobenzyl)oxy)benzaldehyde 

Relevant articles and documents

Synthesis and antimicrobial evaluation of L-phenylalanine-derived C5-substituted rhodanine and chalcone derivatives containing thiobarbituric acid or 2-thioxo-4-thiazolidinone

Four novel series of compounds, including the l-phenylalanine-derived C5-substituted rhodanine (6a-q, 7a-j) and chalcone derivatives containing thiobarbituric acid or 2-thioxo-4-thiazolidinone (9a-e, 11a-e) have been designed, synthesized, characterized, and evaluated for their antibacterial activity. Some of these compounds showed significant antibacterial activity against Gram-positive bacterias, especially against the strains of multidrug-resistant clinical isolates, among which compounds 6c-e, 6g, 6i, 6j and 6q exhibiting high levels of antimicrobial activity against Staphylococcus aureus RN4220 with minimum inhibitory concentration (MIC) values of 2 μg/mL. Compound 6q showed the most potent activity of all of the compounds against all of the test multidrug-resistant clinical isolates tested. Unfortunately, however, none of the compounds were active against Gram-negative bacteria at 64 μg/mL.